



Targeted Delivery of Nanovaccine to Dendritic Cells via DC-Binding Peptides Induces Potent Antiviral Immunity in vivo [Expression of Concern]

Lu Y, Liu ZH, Li YX, Xu HL, Fang WH, He F. *Int J Nanomedicine*. 2022;17:1593—1608.

We, the Publisher and Editor of *International Journal of Nanomedicine*, are issuing an expression of concern for the published article.

Following publication, concerns regarding the integrity of Figure 2A in the article were brought to the Journal's attention. As part of the investigation, the authors were contacted for any information that would help confirm the validity of Figure 2A. Whilst the authors were cooperative, the concerns with Figure 2A still remain.

Therefore, we are unable to fully address the concerns regarding Figure 2A; however, the Editor confirms that the concerns raised about figure 2A do not affect the overall validity or integrity of the reported findings. We advise readers to interpret the information presented in Figure 2A with due caution.

The authors have been notified about this Expression of Concern. Should further information come to light, the journal will reassess any concern raised.

International Journal of Nanomedicine

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-nanomedicine-journal>

<https://doi.org/10.2147/IJN.S518089>

Dovepress
Taylor & Francis Group

